Moxalactam was evaluated in the therapy of lower respiratory tract infections in 40 patients. The most common organisms isolated were Streptococcus pneumoniae (37.2%) and Haemophilus influenzae (21.5%). Gram-negative enteric organisms were isolated from six patients. No The majority of patients were febrile >38.4°C and had an accompanying leukocytosis. All patients had the following laboratory tests before, during, and upon completion of therapy: alkaline phosphatase, serum glutamic oxalacetic transaminase, serum glutamic pyruvic transaminase, total bilirubin, serum creatinine, urinalysis, complete blood count, blood urea nitrogen, and Coombs direct test. In addition, chest roentgenograms, both posterio-anterior and lateral views, were obtained upon completion of the hospitalization of the patients.
Moxalactam was evaluated in the therapy of lower respiratory tract infections in 40 patients. The most common organisms isolated were Streptococcus pneumoniae (37.2%) and Haemophilus influenzae (21.5%). Gram-negative enteric organisms were isolated from six patients. No Because of the potential use of moxalactam as an alternative to the aminoglycoside antibiotics, we elected to treat patients with bacterial pneumonias of all etiologies, both community and hospital acquired. We actively searched for patients with gram-negative bacillary pneumonias, and in 8 of 40 patients (20%) we were able to establish such a diagnosis. We report on the clinical efficacy of moxalactam in this patient population. In addition, a comparative in vitro susceptibility assay on the organisms responsible for these infections was performed with a second-generation cephalosporin, cefamandole, and with a first-generation cephalosporin, cephalothin. 8 h. The majority of patients were febrile >38.4°C and had an accompanying leukocytosis. All patients had the following laboratory tests before, during, and upon completion of therapy: alkaline phosphatase, serum glutamic oxalacetic transaminase, serum glutamic pyruvic transaminase, total bilirubin, serum creatinine, urinalysis, complete blood count, blood urea nitrogen, and Coombs direct test. In addition, chest roentgenograms, both posterio-anterior and lateral views, were obtained upon completion of the hospitalization of the patients.
MATERIALS AND METHODS
Bacteriological studies. All specimens were received in the cooperating microbiology laboratories of the cooperating hospitals. Transtracheal aspirates were plated directly, and sputum was digested with an equal volume of dithiothreitol (Sputazyme, Calbiochem, La Jolla, Calif.) for no more than 15 min, diluted 1:10 with sterile non-bacteriostatic saline and plated onto the following media: sheep blood agar, MacConkey agar, and, in cases of suspected Haemophilus influenzae pneumonia, horse blood agar with 3,000 U of bacitracin cross-streaked with Staphylococcus aureus.
After incubation at 37°C for 18 to 24 h, plates were examined for isolation and identification of potential pathogens. All Interestingly, only five patients in the study were noted to be bacteremic, including 2 of the 19 (10.5%) patients with S. pneumoniae and 3 of the 4 (75%) patients with S. aureus. The latter three patients were all chronic alcoholics with severe pulmonary disease.
No organism was shown to be resistant to moxalactam. All organisms were tested by disk susceptibility or MICs in broth. As shown in Table 2 , the MIC data suggest that the majority of patients would have responded to cefamandole or cephalothin; however, the availability of moxalactam was of considerable benefit in those patients with either Enterobacter spp. or Acinetobacter spp. infections, with the MICs of moxalactam for E. cloacae being 0.19 g/rml as opposed to >25 ,ug/ml for cefamandole and >23.9 ,ug/ml for cephalothin. The pitals. Perhaps reflective of our patient population, H. influenzae was the second most common isolate (9). Of 11 patients with H. influenzae, 8 suffered from chronic alcoholism or chronic obstructive pulmonary disease. Interestingly, 4 of the 11 patients had acquired H. influenzae pneumonia while hospitalized or while residing in a nursing home. The majority (7 of 11), however, were community acquired. In this study, we did not recover any Haemophilus organisms which produce f8-lactamase. However, the overall incidence in our hospitals for such organisms is 4.32% in the 2-year period from June 1978 through June 1980. Overall, the incidence of community-acquired, gram-negative pneumonia was 17.2% (5 of 29 patients). It should be noted that the overall incidence of community-acquired, gram-negative bacillary pneumonia in the same hospital for the year 1973 was 11.3% (12 of 106), as reported by Ebright and Rytel (4) . Whereas previously these patients would have been treated for 14 to 21 days with parenteral antibiotics, our median duration of therapy was 12 days. This represents substantial savings in both time and money.
Although most patients included in this study could have received other antibiotics, two clearly benefited from the use of moxalactam. These patients were infected with A. anitratus (7) and E. cloacae (6), both of which were resistant to all the other antibiotics available except for the aminoglycosides.
Although the majority of patients in this study had community-acquired pneumonias, there was no clear distinction between them and the nosocomial pneumonia patients with respect to the incidence of gram-negative pneumonias (5 of ANTIMICROB. AGENTS CHEMOTHER.
29, community [17.2%]; 3 of 11, nosocomial [27.2%]). In both groups, it is apparent that age and serious predisposing illness may both be significant factors in the development of infection. In our study, the average age of the patients with enteric organisms isolated from their respiratory secretions was 68.3 years (range, 56 to 89), and most had serious predisposing factors. As noted by Ebright and Rytel (4), such pneumonias occur most frequently in elderly people and carry a high mortality rate.
It becomes apparent, then, that in the majority of lower respiratory infections, penicillin, ampicillin, amoxicillin, or cephalothin may be sufficient for adequate treatment. Moxalactam offers a distinctive advantage, however, when the etiological agent cannot be ascertained or when a gram-negative pneumonia is present.
